Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Take a blood pressure pill or undergo renal denervation?

Renal denervation could be a new treatment approach for patients with treatment-resistant hypertension. The findings of the SYMPLICITY HTN-2 trial1 suggested that renal denervation was associated with a major reduction in systolic blood pressure based on office measurements of blood pressure. However, ambulatory blood pressure is the state-of-the-art technique for measuring blood pressure in patients with treatment-resistant hypertension.2 Poor drug adherence is common in treatment-resistant hypertension,3 but this was not monitored in SYMPLICITY HTN-2, making the study susceptible to the Hawthorne effect.